AbbVie and FutureGen announce license agreement for IBD therapy
June 14, 2024Research and Development FutureGen, Gastrointestinal tract, ibd, inflammatory bowel disease
AbbVie and FutureGen Biopharmaceutical have announced a license agreement for the development of FG-M701, a next-generation TL1A antibody for the …
Pfizer shares update on DMD gene therapy clinical trial
June 13, 2024Research and Development DMD, Musculo-skeletal disorder, Pfizer, duchenne muscular dystropy, gene therapy
Pfizer has announced an update from its phase 3 randomised, multicentre, double-blind, placebo-controlled CIFFREO trial, which assessed the investigational mini-dystrophin …
Cara Therapeutics shares data from part a of notalgia paresthetica trial
June 13, 2024Research and Development Cara Therapeutics, Neurology, clinical trial, notalgia paresthetica, pruritus
Cara Therapeutics has announced the outcome from the dose-finding Part A of the KOURAGE-1 study which assessed the efficacy and …
Tracon shares data from phase 2 trial for glioblastoma treatment
June 12, 2024Medical Communications Oncology, Tracon Pharmaceuticals, clinical tria, clinical trial, glioblastoma
Tracon Pharmaceuticals has announced the publication of its phase 2 clinical data for its DNA damage repair inhibitor drug candidate, …
Evotec shares progress in Bristol Myers Squibb neuroscience collaboration
June 12, 2024Research and Development Evotec, Neurology, bristol myers squibb, neuroscience
Evotec has announced that it has reached important scientific progress within the neuroscience collaboration with Bristol Myers Squibb, initiating a …
FDA accepts Eisai’s Leqembi sBLA for early AD treatment
June 11, 2024Medical Communications Alzheimer's, Biogen, FDA, Neurology, sBLA
Eisai and Biogen have announced that the US Food and Drug Administration (FDA) has accepted Eisai’s supplemental biologics license application …
Santhera announces Early Access Program by partner Sperogenix for DMD treatment
June 11, 2024Medical Communications DMD, Musculo-skeletal disorder, early access, muscular dystrophy, santhera
Santhera Pharmaceuticals has announced that its partner Sperogenix Therapeutics has launched a paid-for Early Access Program (EAP) for Agamree (vamorolone) …
Eli Lilly shares results for tirzepatide for MASH resolution
June 10, 2024Research and Development Eli Lilly, Hepatology, MASH, clinical trial, liver
Eli Lilly has announced results from the phase 2 SYNERGY-NASH study which assessed 190 patients, with or without type 2 …
GSK’s Arexvy vaccine approved by FDA for RSV prevention in adult patients
June 10, 2024Medical Communications FDA, GSK, Immunology, Vaccine
GSK has announced that the US Food and Drug Administration (FDA) has approved Arexvy (Respiratory Syncytial Virus (RSV) Vaccine, Adjuvanted) …
Nuclera gains £1.14m funding from Innovate UK
June 7, 2024Research and Development Innovate UK, Nuclera, Pharmacy, grants
Nuclera has announced that it has been awarded two grants from Innovate UK, totalling £1.14m.
FDA approves Geron’s Rytelo for treatment of MDS with transfusion-dependent anaemia
June 7, 2024Medical Communications FDA, Geron, Haematology, anaemia, mds
Geron Corporation has announced that the US Food and Drug Administration (FDA) has approved Rytelo (imetelstat) for the treatment of …
AbbVie initiates phase 3 multiple myeloma trial
June 6, 2024Medical Communications ABBV-383, AbbVie, Oncology, clinical trial, multiple myeloma
AbbVie has announced that it has dosed the first patient in its phase 3 CERVINO trial, which aims to assess …
Syngene launches new platform for protein production
June 6, 2024Research and Development ExcellGene, Pharmacy, Syngene, platform, protein production
Syngene has announced the launch of its new protein production platform, which will utilise a cell line and transposon-based technology …
Gilead shares results from two-year analysis of phase 3 study in primary biliary cholangitis
June 5, 2024Research and Development Gilead, Hepatology, clinical trials, primary biliary cholangitis, seladelpar
Gilead has announced two-year interim results from the ongoing ASSURE study of investigational seladelpar for the treatment of primary biliary …
Sanofi shares phase 3 trial results for Sarclisa in multiple myeloma treatment
June 5, 2024Research and Development Oncology, Sanofi, Sarclisa, clinical trial, multiple myeloma
Sanofi has announced data from the IMROZ phase 3 trial which assessed Sarclisa (isatuximab) in combination with standard-of-care bortezomib, lenalidomide …
Quince Therapeutics gains FDA Fast Track Designation for EryDex System
June 4, 2024Medical Communications EryDex, FDA, Quince Therapeutics, Rare Diseases, fast track designation
Quince Therapeutics has announced that the US Food and Drug Administration (FDA) has granted Fast Track Designation for its EryDex …
Oryzon Genomics announces publication of phase 2a ALICE trial results
June 4, 2024Medical Communications AML, Oncology, Oryzon genomics, acute myeloid leukaemia, clinical trial
Oryzon Genomics has announced that the final results from its phase 2a ALICE study have been published online in The …
CHMP recommends AstraZeneca’s Tagrisso for approval for lung cancer treatment
June 3, 2024Medical Communications CHMP, EMA, Oncology, Tagrisso, lung cancer
AstraZeneca has announced that Tagrisso (osimertinib) alongside pemetrexed and platinum-based chemotherapy, has been recommended for approval in the EU for …
Gilead and Arcus announce results from colorectal cancer treatment trial
June 3, 2024Research and Development Arcus, Gilead, Oncology, clinical trial, colorectal cancer
Gilead Sciences and Arcus Biosciences have announced new data from cohort B of ARC-9, a phase 1b/2 study which aims …
AbbVie gains positive CHMP opinion for Skyrizi for treatment of UC
May 31, 2024Medical Communications AbbVie, EMA, Gastrointestinal tract, Skyrizi, ulcerative colitis
AbbVie has announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has granted a …
Latest content
Long-acting therapies set to reshape HIV treatment market
MHRA approves Romvimza for tenosynovial giant cell tumour
